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5ABSTRACT
 Aims The four studies in this thesis highlight both undetected hypertension and hyper-
tension in patients receiving extensive blood pressure treatment. The aim of the fi rst 
study was to investigate whether, and by which blood pressure measurements, one can 
predict the probability of future hypertension by analyzing the blood pressure response 
during exercise testing. The second study aimed to investigate the prevalence of treat-
ment resistant hypertension (TRH) i.e. patients who do not reach target blood pressure 
despite treatment with three or more antihypertensive drugs. The aim was further in the 
third study to describe cardiovascular outcomes in a TRH population. The fourth study 
compared the two-year medication adherence to antihypertensive treatment in patients 
with controlled and uncontrolled hypertension. The overall aim of this thesis was to 
give rise to increased knowledge regarding hypertension in clinical practice.
Methods In study I, a cohort of patients without known hypertension or cardiovascu-
lar disease who performed exercise testing for various reasons during 1996-1997 was 
investigated. Blood pressure data from the exercise test were used to predict hyper-
tension. Ten years after the exercise test, a questionnaire evaluating development of 
hypertension was carried out. In study II-IV, data from the Swedish Primary Care Car-
diovascular Database (SPCCD) were used. In the SPCCD, data from medical records 
of hypertensive patients aged ≥30 from 48 primary health care centres in two regions in 
Sweden, collected between 2001 and 2008, are linked to fi ve Swedish population based 
registers. In study II the prevalence of  TRH according to the different prevailing TRH-
defi nitions from the treated hypertensive population was evaluated. Study III analysed 
the association between TRH and cardiovascular events with adjustment for important 
confounders in the SPCCD from 2006 and with follow-up in the population based reg-
isters until 2012. Patients with known cardiovascular co-morbidity were excluded. Data 
on antihypertensive drug dispenses were derived from the Prescribed drug registry. In 
study IV the change in medication adherence, measured by proportion of days covered 
(PDC), over two years was evaluated for patients with both controlled and uncontrolled 
hypertension, dispensed three or more antihypertensive drugs. In studies II-IV high 
medication adherence was defi ned as PDC ≥80%.
Results Higher blood pressure before the exercise test and a rapid rise in blood pres-
sure during the test resulted in an increased risk of hypertension ten years post exercise 
testing. Treatment resistant hypertension is present in 8-17% of hypertensive patients in 
Swedish primary care. The increased risk of cardiovascular events in this population is 
mainly associated with an increased risk of heart failure. Antihypertensive medication 
adherence does not seem to differ between patients achieving target blood pressure and 
patients with treatment resistant hypertension.
Conclusions Modifi ed blood pressure screening during an exercise test can help iden-
tify patients with increased risk of developing hypertension. Treatment resistance to 
antihypertensive treatment is not a negligible problem, and these patients have an in-
creased risk of heart failure despite adherence to antihypertensive treatment. Awareness 
of high blood pressure and adherence to antihypertensive treatment must be increased 
in order to reduce the burden of disease caused by high blood pressure. 
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7 SAMMANFATTNING PÅ SVENSKA
Bakgrund
Högt blodtryck är en vanligt förekommande sjukdom. Cirka 50% av alla vuxna per-
soner i Sverige över 65 års ålder beräknas vara drabbade och i hela den vuxna befolk-
ningen i världen beräknas drygt 20% ha förhöjt blodtryck. Riskerna för att drabbas av 
stroke, hjärtinfarkt, hjärtsvikt eller nedsatt njurfunktion är betydligt högre för de in-
divider som har högt blodtryck jämfört med de som har normalt blodtryck. De ökade 
riskerna som är förknippade med förhöjt blodtryck kan till stor del minskas med den 
behandling som idag är lättillgänglig och effektiv. Ett problem med högt blodtryck är 
att symtomen är få vilket bidrar till att många är ovetande om sitt förhöjda blodtryck. 
Ett annat problem är att många patienter med högt blodtryck inte når målblodtryck 
trots behandling. Personer med högt blodtryck trots behandling med fl era läkemedel 
tros utgöra en specifi k grupp som kräver större behandlingsinsatser. En av orsakerna 
till dåligt reglerat blodtryck kan vara dålig följsamhet till läkemedelsbehandling vilket 
är en stor utmaning för en sjukdom med få symtom.
Syfte
Det övergripande syftet med denna avhandling var att skapa mer kunskap kring högt 
blodtryck i den kliniska vardagen. Avhandlingens fyra delarbeten belyser både oupp-
täckt högt blodtryck och högt blodtryck hos individer med omfattande läkemedelsbe-
handling. Syftet var att studera om, och med vilket blodtrycksmått, man kan förutsäga 
om en person kommer att få högt blodtryck senare i livet genom att analysera blod-
trycksreaktionen under belastning i form av ett arbetsprov på träningscykel. Vidare 
syftade avhandlingen till att i en stor primärvårdskohort med vuxna patienter med 
högt blodtryck undersöka hur många patienter med läkemedelsbehandlat högt blod-
tryck som inte uppnår målblodtryck trots behandling med tre, eller fl er läkemedel (be-
handlingsresistent högt blodtryck). Syftet var också att kartlägga utfallet avseende to-
taldöd, död orsakad av hjärt-/kärlsjukdom, stroke och hjärtsvikt i denna patientgrupp. 
Det fjärde delarbetets syfte var att jämföra den tvååriga följsamheten till omfattande 
läkemedelsbehandling hos personer med välbehandlat respektive icke välbehandlat 
högt blodtryck. 
Resultat
Högre blodtryck före start av arbetsprov samt snabb stegring av blodtryck under ar-
betsprov resulterade i förhöjd risk att drabbas av diagnosen högt blodtryck tio år efter-
genomfört arbetsprov. Av de individer i en svensk primärvårdsbefolkning som erhål-
ler tre eller fl er läkemedel mot högt blodtryck har 8-17% trots denna behandling inte 
välreglerat blodtryck. Risken att drabbas av hjärt-/kärlsjukdom i denna patientgrupp 
var framförallt kopplad till en ökad risk för hjärtsvikt. Gruppen uppvisade dock inte 
någon ökad risk att insjukna i stroke jämfört med patienter utan behandlingsresistent 
högt blodtryck. Läkemedelsföljsamheten verkar inte skilja sig mellan patienter som 
uppnår målblodtryck respektive patienter som inte når uppställda mål.
8Slutsats
Modifi erad screening vid arbetsprov kan bidra till att patienter med ökad risk för högt 
blodtryck identifi eras. Dålig måluppfyllelse avseende blodtryck hos individer med 
omfattande läkemedelsbehandling är vanligt och denna grupp av patienter har en ökad 
risk att drabbas av hjärtsvikt trots att följsamheten till behandling är jämförbar med 
individer som uppnår uppställda blodtrycksmål. Medvetenheten om högt blodtryck, 
måluppfyllelsen för patienter med högt blodtryck och följsamheten till behandling 
mot högt blodtryck måste öka om sjukdomsbördan orsakad av högt blodtryck ska 
kunna minska. Både professionen och patienten behöver tydliga mål för behandling 
och en tydlig struktur avseende uppföljning för att behandlingsresultatet skall bli bra.
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ABBREVIATIONS
 ABPM    Ambulatory blood pressure measurement
ACE   Angiotensin converting enzyme
ATC   Anatomic therapeutic chemical 
aTRH   Apparent treatment resistant hypertension
BMI   Body mass index
DBP   Diastolic blood pressure
eGFR   Estimated glomerular fi ltration rate
ESH   European Society of Hypertension
HBPM   Home blood pressure measurement
ICD    International classifi cation of disease
LDL    Low density lipoprotein
PDC   Proportion of days covered
PHCC   Primary health care centre
RCT   Randomized controlled trial
RDN   Renal denervation
SBP   Systolic blood pressure
SPCCD   Swedish Primary Care Cardiovascular Database
TIA   Transient ischemic attack
TRH   Treatment resistant hypertension
WHO   World Health Organization
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INTRODUCTION
H ypertension is the most important contributor to global burden of disease world-wide (1). Despite the evident risks for life threatening disease and death that 
high blood pressure constitute and the known benefi ts of treatment many patients do 
not reach blood pressure goals (2; 3). 
History
The fi rst time blood pressure was measured was by the priest and botanic Stephen 
Hales in 1769. He measured the blood pressure of a horse in the carotid artery by 
inserting a brass tube connected to a water column. The blood rose to about 8 feet, 8 
inches, about 180 mm Hg and then sunk gradually to zero and the horse died. Luckily, 
about 100 years later the sphygmomanometer for measuring blood pressure around 
the forearm was invented, a technique still in use (4).
Blood pressure measurement
Today blood pressure at clinical appointments (offi ce blood pressure) is, measured in 
a standardized way after 5-10 minutes of rest and after avoiding coffee, tobacco and 
heavy exercise 30 minutes before the measurement. The patient should be in a supine 
or seated position, resting their back and having the feet on the fl oor. The arm should 
be resting at the same level as the heart (5). To avoid under- or overestimations the 
right width of blood pressure cuff is essential (6; 7). In manual measurement of blood 
pressure, after fi lling the cuff with air you release it slowly and use your stethoscope 
to listen for the Korotkoff sound in the brachial artery. What you hear is the turbulent 
fl ow in the artery when the pressure off the cuff is equal to the pressure that the left 
ventricle of the heart, i.e. systolic blood pressure. As pressure drops in the cuff when 
air is released there will be repetitive pulse beats of turbulent blood fl ow until the cuff 
pressure is the same as the diastolic blood pressure and no turbulence is present (8). 
Automated blood pressure measurements performed in the clinic are suggested to 
replace manual offi ce blood pressure since they seem to have a better correlation with 
out of offi ce blood pressure values (9). The difference from standard offi ce blood 
pressure measurement is that the patient is left alone in the examination room with 
an automated, oscillometric blood pressure measurement device around the forearm. 
Repeated measurements are performed and a mean value of these readings is reported. 
The advantage of this technique is reduced artefact from white-coat effect and hence 
reduced unnecessary treatment (10).
Ambulatory blood pressure measurement (ABPM) is highly recommended when di-
agnosing hypertension, especially in patients with suspected white coat effect i.e. high 
offi ce blood pressure but normal out of offi ce blood pressures. ABPM is performed 
during 24 hours when the patients wear a portable blood pressure measurement device 
with repeated blood pressure measurements during day and night and perform normal 
daily life activities (11).
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Home blood pressure measurement (HBPM), using an automated oscillometric blood 
pressure device, is a measurement technique with increasing usage. Recommenda-
tions state that the patient should measure blood pressure repeatedly, in the morning 
and at night during seven days and a calculation of the mean value is used for evalu-
ation (12). 
It has been suggested that out of offi ce blood pressure measurement carries bet-
ter prognostic information than offi ce blood pressure measurements (13; 14). Also, 
HBPM is described to improve medication adherence and blood pressure control from 
an investigation where self-titration of antihypertensive medications was performed 
(15).
Blood pressure development during life
During a life time blood pressure changes although differently for women and men 
were young women have lower systolic and diastolic blood pressure levels than young 
men (16). After the age of fi fty the systolic blood pressure of women increases further 
reaching the same levels as men, and surpasses men in the most elderly population 
(17). The reasons for this are not totally understood but hormonal factors are thought 
to be part of the explanation. 
Blood pressure is a result of several factors such as cardiac output, blood volume and 
arterial diameter and stiffness. It is known from population studies that the cause of 
the systolic blood pressure rise in elderly hypertensive patients is linked to stiffening 
of large arteries while increase in diastolic blood pressure in middle age hypertensive 
patients is related to the total peripheral resistance in primarily arterioles (16). Several 
factors such as high cholesterol levels, smoking, and diagnosis of diabetes/insulin 
resistance are involved in the development of arteriosclerosis which in turn, leads to 
stiff arteries. Life-style factors such as diet and daily physical activity are components 
that contribute to the development of vascular changes, and partially explain the age 
related blood pressure increase found in urban compared to populations living a tradi-
tional life-style without contact to civilization (18).
Defi nition of hypertension
The defi nitions of hypertension are the same in different parts of the world. The pre-
vailing guidelines are ESH 2013 (European), JNC 8 (North-American) and NICE-
criteria (British) (5; 19; 20). To diagnose hypertension repeated offi ce blood pressure 
measurements at different occasions are required. According to guidelines there is a 
grading of hypertension according to blood pressure levels (Table 1).
Etiology of hypertension 
The majority (95%) of patients with hypertension are defi ned as having primary hy-
pertension where no specifi c causative factor can be identifi ed. Genetic predisposi-
tion and multiple life-style dependent factors such as overweight, sedentary life-style, 
smoking, alcohol consumption, sleep-apnea, stress and smoking are involved in the 
preservation of blood pressure increase (4).
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Table 1. Defi nitions and classifi cation of offi ce blood pressure levels (mm 
Hg). ESH/ESC guidelines for the management of arterial hypertension. 
Published by Mancia G. et.al. in European Heart Journal 2013.
Patients with a specifi c cause of hypertension are defi ned as having secondary hyper-
tension. Secondary causes to hypertension should be considered in younger patients 
and in patients where blood pressure is diffi cult to control. Conditions associated with 
secondary hypertension are mainly hormonal such as primary aldosteronism, hyper-
thyreosis, Cushing and feochromocytoma. Apart from primary aldosteronism, which 
has a prevalence of 5-10% in the general hypertensive population, these conditions 
are rare (21). Renal artery stenosis, coarcatio aorta and other congenital or acquired 
vessel or heart diseases may also be considered in relation to secondary hypertension 
(4). 
Hypertension prevalence
The prevalence of hypertension in the adult population in Sweden was, through lim-
ited screening studies, estimated to approximately 27% according to the systematic 
literature review “Moderately Elevated Blood Pressure” published by the Swedish 
council on Technology Assessment in Health Care in 2004 (22). From the national 
public health survey in Sweden 2015 it is estimated that hypertension has a prevalence 
of approximately 20% in the entire adult population, rising to around 50% in individu-
als over 65 years (23). 
In 2005 it was estimated that 29% of the world population would suffer from hyper-
tension in 2025 (24). The World Health Organization, WHO, has estimated that right 
now 1 billion individuals worldwide suffer from hypertension (25). Unpublished data 
from the “PURE” study reveals decreasing prevalence of hypertension in western 
high-income countries (26). Further, in a pooled analysis of 19.1 million participants 
worldwide, published in 2016, the global age-standardised prevalence of hypertension 
was 24% for men and 20% for women. However, hypertension prevalence has shifted 
in geographical trends during the last forty years. The highest numbers are now found 
in low-income countries in south Asia and sub-Saharan Africa (27). 
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Hypertension awareness
It is a global challenge to fi nd strategies for good blood pressure control. Already in 
1972 the concept “rule of halves” was introduced (28). Largely this imply that 50% 
of hypertensive patients are aware of their condition, 50% of the aware patients have 
treatment and 50% of the treated patients have suffi cient treatment and reach target 
blood pressure. There are indications that this rule still exists in the hypertensive pa-
tient population as suggested by Weinehall et. al. in 2002 (29). A slight trend towards 
better control rate has been seen in parts of the world like northern Sweden (30) and 
Canada (31). One Swedish publication even suggest that the awareness, treatment end 
control rate now follow the “rule of thirds” (32).
One way to handle the problem of hypertension unawareness could be to introduce 
a screening program in the community since the consequences of undiagnosed and 
untreated hypertension on a group level are important. The issue of screening has 
been a current issue during many years and the WHO criteria for screening, published 
by Wilson and Jungner in 1968, are to a large extent met in hypertension (33). The 
criteria state that the disease in question should have a latent/symptom-free phase, be 
an important health problem which is possible to diagnose with a suitable test and that 
there should be an agreed policy on how to treat the condition. One important crite-
rion is however not met, namely the cost-benefi t criteria. It would be far too costly to 
screen the whole adult population, in other words it is not considered cost-effective. 
The report on hypertension from the Swedish council on Technology Assessment in 
Health Care established in 2004 that there is no indication for blood pressure screen-
ing of the whole population but so called opportunistic screening could be applied 
(22). This was also emphasized by Vasan et. al. who conclude that screening for hy-
pertension in high-risk patients can be cost-effective (34). This approach seems rea-
sonable and applicable to today’s health care.
Blood pressure during exercise testing
One way to perform opportunistic screening is to interpret and react to every single 
raised blood pressure that is obtained in health care. The population referred for exer-
cise testing is diverse in terms of cardiovascular risk profi le and not always classifi ed 
with high risk. According to guidelines for exercise testing the individuals with inter-
mediate cardiovascular risk presenting with chest pain could be evaluated for isch-
emic heart disease with exercise testing (35). Generally exercise testing is indicated 
for investigation of suspected ischemic heart disease, arrhythmias and assessment of 
physical capacity and is also a useful tool for prognostic considerations in coronary 
artery disease (36). The normal blood pressure reaction to exercise is that vagal tone is 
withdrawn and sympathetic stimulation increased which leads to an increase in heart 
rate, stroke volume, cardiac output and initially in peripheral resistance resulting in a 
blood pressure increase.
During exercise testing blood pressure is monitored repeatedly, mainly to fi nd indica-
tions on coronary artery disease such as a sudden decrease in blood pressure or a fail-
ure to increase blood pressure during exercise (37). A drop in blood pressure during 
exercise indicates that the test must be terminated, likewise a systolic blood pressure 
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≥250 mm Hg is a relative indication for test termination. When we initiated study I 
for this thesis the clinical question was how to interpret and handle blood pressure 
response during exercise. The exaggerated blood pressure response to exercise had 
already been suggested by several investigators as a predictor for both hypertension 
(38-42), cardiovascular disease and death (43; 44). However, there was no consensus 
on which blood pressure measurement during exercise that was the best predictor of 
future hypertension. Some investigators suggested a cut-off between 200-230 mm 
Hg (40) to defi ne hypertensive reaction to exercise and yet others suggested recovery 
blood pressure after exercise to be a valid predictor for future hypertension (42). A 
number of scientifi c investigations on blood pressure reaction during exercise tests are 
performed only in middle-aged healthy men resulting in a problem of generalizability 
(45). The diversity in results from previous studies due to different populations, differ-
ent methodology and different blood pressure measurements made us initiate study I, 
and our aim was to identify the blood pressure reaction with the best prognostic value 
regarding future hypertension.
Treatment of hypertension
According to hypertension guidelines antihypertensive drug treatment should be ini-
tiated fi rst after life-style interventions such as increase in physical activity, losing 
weight, smoking cessation, reduced alcohol intake and initiating a diet with less fat, 
salt and more vegetables. At the same time, to await results from life-style changes 
should not postpone the initiation of drug therapy (5). Numerous studies have shown 
that these interventions can be effective in reducing blood pressure (46) but also that 
it is hard to be compliant to these life-style changes especially in the long term (47). 
For example, loosing 5 kg of weight may reduce blood pressure by approximately 4 
mm Hg (48) and physical activity, such as aerobic exercise, has been shown to reduce 
systolic blood pressure by 7 mm Hg (49) or as much as 11 mm Hg in hypertensive 
patients depending on the dose and form of exercise (50).
Initiation of antihypertensive drug treatment should be performed when life-style 
changes have not had suffi cient effect on reducing blood pressure. The intensive de-
velopment of different antihypertensive agents during the 80s and 90s has resulted 
in a variety of antihypertensive drugs to choose from. Already in 2004 the Swedish 
report on hypertension established that the three most effective and best tolerated 
antihypertensive drug classes were thiazide diuretics, angiotensin converting enzyme 
(ACE) inhibitors/angiotensinogen receptor blockers and calcium channel blockers. 
From numerous randomized controlled trials (RCT), it is well documented that these 
drug classes have equal blood pressure reduction capacity, result in the same risk 
reduction and are fairly equal in tolerability (22). Prevailing international guidelines 
from Europe, Great Britain and North America agree on these three agents being the 
fi rst choice for antihypertensive treatment initiation. However, European Society of 
Hypertension (ESH) guidelines also include beta-blockers in fi rst line treatment even 
though there are confl icting results on the risk-reducing effect by beta-blockers (51). 
Often there is need for more than one antihypertensive drug class to control blood 
pressure and combination therapy with several recommended agents is needed (Fig-
ure 1). When evaluating the hypertensive patient it is also important to have the broad 
perspective of the cardiovascular risk profi le including parameters such as body mass 
18
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Figure 1. Possible combinations of classes of antihypertensive drugs. Green continuous 
lines: preferred combinations; green dashed line: useful combination (with some limita-
tions); black dashed lines: possible but less well-tested combinations; red continuous line: 
not recommended combination. Although verapamil and diltiazem are sometimes used with 
a beta-blocker to improve ventricular rate control in permanent atrial fi brillation, only di-
hydropyridine calcium antagonists should normally be combined with beta-blockers. Pub-
lished by Mancia G. et.al. in European Heart Journal 2013.
index (BMI), lipids, blood glucose and renal function. It is recommended to assess 
these other risk factors and consider them when evaluating the total risk for cardio-
vascular events and chronic kidney disease. A helpful tool for estimating the total 
cardiovascular risk in patients is the SCORE diagram. This risk chart can give an as-
sessment of the absolute risk of suffering from a cardiovascular event within ten years 
and consider age, gender, blood pressure level, level of total cholesterol and smoking 
status (52). The limitations of the SCORE diagram are, among other aspects that the 
estimation does not consider diagnose of diabetes and does not give the absolute risk 
for individuals above 65 years of age. 
Optimal target blood pressure level
The optimal target blood pressure for individuals with different cardiovascular risk 
profi le is under debate. There is a consensus in prevailing guidelines that optimal 
blood pressure goal should be <140/90 mm Hg in adult individuals. Only the Ameri-
can guidelines recommend a blood pressure level of <150/90 mm Hg in the general 
population aged ≥60 years. Observational data indicate that it is benefi cial for the 
stroke risk with a blood pressure down to at least 115/75 mm Hg (53). More recently 
the association between blood pressure level in different age groups and different car-
diovascular diseases were thoroughly investigated and presented with the conclusion 
that the lower blood pressure (90-114 mm Hg), the better outcome in all age-groups 
and for all cardiovascular diseases (2). The debate regarding appropriate target blood 
pressure level is even more intense since the publication of a randomized control trial 
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in non-diabetic patients with high cardiovascular risk where it was found that patients 
with more strict systolic blood pressure control (<120 mm Hg) had a more benefi cial 
outcome regarding fatal and nonfatal major cardiovascular events and death and all-
cause mortality (54). Major criticism has been raised against the methodology of the 
study, especially against the blood pressure measurements that were performed with 
an unobserved automated offi ce blood pressure registration (55).
Earlier guidelines recommended a lower blood pressure target for diabetic patients but 
because of lack of proof from RCT´s that blood pressure <130/80 mm Hg could infl u-
ence major cardiovascular events the shift to higher blood pressure targets for patients 
with diabetes type 2 has been performed (56). In Sweden the current recommended 
blood pressure target for patients with diabetes type 2 is <140/85 mm Hg and was 
a consensus agreement published in 2014 (57). Future investigations will hopefully 
clarify this complicated and important question. 
Another subject under current debate is whether the “J-curve-phenomenon” applies 
to hypertensive patients, especially hypertensive patients with diabetes. The J-curve-
phenomenon refers to an observation that it seems to be a linear relation between 
blood pressure level and outcome where lower is better but only down to a certain 
point where the curve turns up again suggesting that really low blood pressures could 
be associated with worse outcome. It could also be that low blood pressure is associ-
ated with higher degree of comorbidity, which of course would infl uence outcome. It 
is important to evaluate whether the blood pressure is low due to natural cause or is 
an effect of treatment. In an observational study by Adamsson-Eryd and co-workers 
the J-curve seems to uncurl when outcome is evaluated in a population with diabetes 
without obvious cardiovascular disease showing the highest outcome benefi ts in pa-
tients with the lowest blood pressure (110-119 mm Hg) (58).  
Treatment resistant hypertension
Defi nitions of treatment resistant hypertension
European guidelines advocate the defi nition of treatment resistant hypertension 
(TRH) to be uncontrolled blood pressure (>140/90 mm Hg offi ce blood pressure) de-
spite treatment with 3 or more antihypertensive drug classes of which one is a thiazide 
diuretic (5). The defi nitions of TRH differ to some extent between North America and 
Europe where the largest difference is that American guidelines also include patients 
who have a controlled blood pressure (<140/90 mm Hg) on 4 or more antihyperten-
sive drug classes, of which one is a diuretic if tolerated (59).
True/apparent treatment resistant hypertension
The defi nitions of TRH all require that secondary cause of hypertension has been 
excluded. The secondary causes are mentioned above but there are also causes that 
are not related to specifi c diagnoses but to poor blood pressure technique, medication 
non-adherence or the white-coat effect (59). These causes can be summarised as pseu-
do resistance to treatment. When studying the hypertensive population a term called 
apparent TRH (aTRH) is often used. This means that all possible causes of uncon-
trolled hypertension have not been excluded in an integrated way but the patient fulfi ls 
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Figure 2. Venn diagram of the prevalence of resistant hypertension. Area of subpopulations 
drawn to scale with estimated prevalences in percentages. Prevalences were estimated pri-
marily from epidemiology studies performed within the United States.*Estimated prevalence 
among all hypertensive individuals. Published by Judd E. et.al. in J Hum Hypertens. 2014 
Aug; 28(8): 463-468
the criteria for TRH (60). The term true TRH refers to uncontrolled hypertension both 
in the offi ce blood pressure measurement and in the 24-h ambulatory blood pressure 
measurement. The proportions of these populations are illustrated in Figure 2. 
Renal denervation – a plausible therapy for resistant hypertension
Around 2009 the interest for TRH grew immensely since the introduction of inva-
sive therapeutic possibilities such as renal denervation (RDN). The theory of RDN 
mechanism is to diminish the sympathetic drive on blood pressure by reducing the 
sympathetic nerve activity in the renal arteries through catheter based technique (61). 
The market for devices for performing these new techniques grew rapidly and RDN 
was performed in Europe, mostly in Germany, and the North America. Positive re-
sults regarding blood pressure lowering effect was seen in uncontrolled trials (62). 
To be able to study the effect of RDN in a more controlled way a study program was 
initiated to perform controlled studies in different ways and fi nally a sham-controlled 
study (SYMPLICITY III trial) was carried out (63).
In Sahlgrenska University Hospital a multidisciplinary Health Technology assess-
ment was performed before the planned introduction of RDN. During that process it 
was evident that the prevalence of TRH in Sweden was unknown. If RDN was to be 
implemented as a standard method of treating hypertension in the future it would be 
necessary to have an estimation of how many patients that could be eligible for this 
technique. Hence, study II was initiated where we aimed at describing the prevalence 
of TRH in primary health care in Sweden. 
21
Hypertension prognosis
It is estimated that the life expectancy in hypertensive men and women is 5.1 and 4.9 
years shorter compared to normotensive individuals (64). The increased risk for car-
diovascular and chronic kidney disease that hypertension carries can to a great extent 
be diminished by effi cient treatment (3). In a large population study in primary care 
the association between blood pressure levels and different specifi c cardiovascular 
outcomes were analyzed. This study showed that peripheral artery disease and heart 
failure are common early manifestations of target organ damage in relation to blood 
pressure (2). From the Swedish heart failure registry we know that 61% of patients 
with heart failure with preserved ejection fraction have hypertension (65). Further it 
is also well known that the risk for atrial fi brillation is higher in hypertensive patients 
(66). 
The prognosis for patients with TRH is less thoroughly studied. We know from sub 
studies of clinical trials like “ALLHAT” that patients with TRH have worse prognosis 
compared to patients with controlled hypertension (67). Also, in a North American co-
hort study of >200 000 hypertensive patients the patients with TRH had an increased 
risk of cardiovascular events (68). Thus, in study III we aimed to evaluate the cardio-
vascular risk associated with TRH in Swedish primary care.
Medication adherence
“Keep a watch on the faults of the patients, which often make them lie about the 
taking of things prescribed” Hippocrates
Medication adherence is a challenging task in all chronic illnesses and is estimated by 
WHO to be approximately 50%. The defi nition of medication adherence suggested by 
the WHO is “the extent to which a person´s behaviour corresponds with agreed rec-
ommendations from a health care provider” (69). In a population based study, healthy 
individuals were asked how much longer survival it would be required for them to 
make it worth taking a prescribed medicine. Twelve percent reported that it would 
be required ten years of extended life-time for them to fulfi l the prescribed treatment 
(70). The barriers to comply with treatment were reviewed in 2011 and could be cat-
egorized into patient related, physician related and health care system related (71). 
Hypertension is a disease with few symptoms which makes medication adherence 
even more challenging (72). We know from a Swedish study that the adherence over 
time to antihypertensive medication decreases with 26% during the fi rst year of treat-
ment in incident hypertensive patients (73). Decline in medication adherence over 
time has also been described in secondary prevention after stroke (74), after myo-
cardial infarction (75) and in heart failure patients (76). Low medication adherence 
in hypertension is associated with young age, male sex and mild-to-moderate blood 
pressure elevation (73). Drug class, however, does not seem to have an association to 
medication persistence (77). There is solid evidence that high adherence to antihyper-
tensive treatment results in reduction of cardiovascular risk. For example 10% lower 
risk for coronary artery disease (78), 11% lower risk for heart failure (79) and 22% 
lower risk for cerebrovascular disease have been found in relation to antihypertensive 
treatment adherence (80).
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Medication adherence in treatment resistant hypertension
In apparent TRH low medication adherence is a common cause of uncontrolled blood 
pressure (81). In a recent review the prevalence of insuffi cient medication adherence 
in apparent TRH was varying between 7 and 66% in different populations and as a 
result of different adherence measurements (82).
We initiated study IV after the SYMPLICITY III trial results were made offi cial (63). 
This fi rst sham-controlled RDN study did not show a signifi cant blood pressure reduc-
tion as a result of active treatment. These results were surprising to many hypertension 
researchers and immediately a debate was initiated dealing with factors that could 
have infl uenced the results. One criticism was directed towards the fact that some 
operators only did one single RDN within the study program. Maybe this could have 
led to a low quality in the procedure. Also the medication adherence during the study 
was not thoroughly monitored and therefore it cannot be ruled out that an enhanced 
medication adherence in both groups would have infl uenced the results. This is de-
fi ned as the Hawthorne effect and imply that people who know that they are being 
observed (controlled) within a study often act differently than they regularly do (83). 
It is possible that all patients in the SYMPLICITY III study had an enhancement of 
medication adherence and therefore the blood pressure control was increased in both 
groups. It has even been suggested that TRH does not exist in a patient population 
with perfect medication adherence (84). Also, it is suggested that screening for medi-
cation non-adherence should be mandatory before classifying patients with TRH (5). 
This scientifi c discussion emphasize the importance of medication adherence, and 
constitutes the background to study IV where we aimed at investigating the adherence 
to treatment in hypertensive individuals dispensed 3 or more drug classes comparing 
TRH with non TRH patients. 
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AIMS
Study I
To identify the best blood pressure measurement for predicting future hypertension 
during exercise testing. Further, we aimed to create a feasible risk chart regarding 
blood pressure reaction during exercise that could predict the risk of future hyperten-
sion in the clinical setting.
Study II
To determine the prevalence of treatment resistant hypertension (TRH) according to 
different defi nitions in a hypertensive cohort with known medication adherence in 
primary health care in Sweden. Further we aimed to evaluate the use of mineralo-
corticoid receptor antagonists in TRH and to describe the association of different co-
morbidities in this patient group. 
Study III
To assess the risk for cardiovascular morbidity and mortality, beyond blood pressure 
level, in patients with treatment resistant hypertension (TRH) compared to hyperten-
sive patients with no TRH in a primary care setting of hypertensive patients.  
Study IV
To describe the medication adherence over a time period of two years in patients with 
treatment resistant hypertension. We also aimed to compare the adherence to a popu-
lation of patients with controlled blood pressure treated with three or more antihyper-
tensive drug classes and to fi nd factors associated with change in adherence over time.
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PATIENTS AND METHODS
Study I
All patients (N=1047) who performed an exercise test at the Department of Clinical 
Physiology at Sahlgrenska University hospital/Östra between May 1996 and Decem-
ber 1997 were considered for inclusion in the study. Individuals who already had hy-
pertension or antihypertensive treatment, had moved abroad or who had died during 
follow up were excluded (n=441). In 2006 and 2007 we distributed questionnaires to 
the remaining 606 patients. The questionnaire included questions on whether the pa-
tient had developed hypertension or started antihypertensive treatment during follow 
up (Figure 3).
The exercise test was performed after referral from either primary health care or cur-
rently hospitalized patients or as part of health examinations. The most common cause 
for referral was chest pain. The test was performed according to the Bruce protocol, 
a graded symptom-limited test with bicycle ergometry (85). All blood pressures were 
measured manually with auscultatory technique by the attending nurse.
We considered different blood pressure measurements during the exercise test as pre-
dictors for development of hypertension including systolic blood pressure (SBP) at 
rest before the test, maximal SBP, SBP rise rate and SBP during recovery. 

Figure 3. Flow chart of the study population in study I.
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The Swedish Primary Care Cardiovascular Database (SPCCD) (Study II-
IV)
Clinical data from 74 751 patients attending primary care with hypertension accord-
ing to International Classifi cation of Diseases 10th revision codes (ICD-10), were col-
lected From 1 January, 2001 through 31 December, 2008 into the Swedish Primary 
Care Cardiovascular Database (SPCCD). The SPCCD included all patients age ≥30 
years with a recorded diagnosis of hypertension visiting any of the 48 participating 
primary health care centers (PHCCs) during the time period. The PHCCs were 24 out 
of 25 available PHCCs in the rural region of Skaraborg and a selection of 24 PHCCs 
from the urban region of south west Stockholm, Sweden. Data on age, sex, BMI, 
smoking status, co-morbidity and blood pressure levels were derived from electronic 
medical records from single visits (86). Using unique personal identifi cation numbers 
made it possible to link the data extracted from medical records to the Prescribed Drug 
Register, the National Patient Register and the Cause of Death Register. Furthermore, 
the data was synchronized with Census data (migration, country of birth) and National 
registers of education and income from Statistics Sweden (Figure 4). The Prescribed 
Drug Register has a full coverage of the dispensed prescriptions to the whole popula-
tion of Sweden since 2005 (87). 
The PHCCs were recommended to follow national guideline recommendations for 
blood pressure measurements. Offi ce blood pressure was measured in a seated or 
supine position, according to prevailing recommendations, by a physician or a nurse 
using either oscillometric or auscultatory measurement techniques. 

Figure 4. The Swedish Primary Care Cardiovascular Database (SPCCD). Data from 48 
primary health care centres. *Registers held by the Swedish National Board of Health and 
Welfare. **Register held by Statistics Sweden.
Study II
This registry-based descriptive study was limited to patients, in the SPCCD, who had 
a valid recorded blood pressure after July 1, 2006 (N=59 032), were treated with at 
least one antihypertensive drug, and who had identifi able dispensed drugs in the Pre-
scribed drug registry after January 1, 2006. Number of excluded patients are visual-
ized in Figure 5.
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We assessed different defi nitions of TRH according to European and American guide-
lines (5; 59). 
The index blood pressure was the fi rst measured blood pressure after July 1st 2006 in 
the database.
All the defi nitions included the index blood pressure and 3 or more antihypertensive 
medications. We described both uncontrolled TRH (BP ≥140/90 with 3 or more drugs) 
and controlled TRH (BP <140/90 with 4 or more drugs). We also specifi cally calcu-
lated the prevalence of treatment resistant hypertension in patients treated with min-
eralocorticoid receptor antagonists. The complete defi nitions are presented in Table 
2 page 32. We considered drugs dispensed up to 180 days prior to the index blood 
pressure. To assess the medication adherence we calculated the “Proportion of Days 
Covered” (PDC). This is a measurement based on the number of days the patient is 
supplied medication during a specifi c time interval (88). An elevated blood pressure 
with an average PDC ≥80 % is the defi nition of TRH used, hence an average PDC for 
the individual antihypertensive drug classes for each patient was calculated. 
Figure 5. Flow chart of study population in study II.
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Study III
In this cohort-study we compared the outcome of patients with TRH to patients with 
non TRH and used the same patient cohort from the SPCCD as in study II. With re-
spect to TRH we restricted the analysis to defi nitions including uncontrolled TRH. 
Hence, patients with blood pressure ≥140/90 despite treatment with 3 or more anti-
hypertensive drug classes were defi ned as TRH whereas the treated hypertensive pa-
tients, regardless of blood pressure level, constituted the control group. Patients who 
were diagnosed with ischemic heart disease, heart failure, stroke or transient ischemic 
attack (TIA) prior to the index blood pressure were excluded. All exclusion criterias 
and numbers of excluded patients are presented in the fl ow-chart (Figure 6).

Figure 6. Flow chart of the study population in study III. BP=Blood pressure, HT=Hypertension, 
HTN=non-treatment resistant hypertension, TRH=Treatment resistant hypertension.
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The outcome parameters were cardiovascular mortality, all cause mortality, ischemic 
heart disease, heart failure, stroke and TIA. Data on outcome was retrieved from the 
National Patient register for ICD-diagnoses from both outpatient clinics and hospitals 
and the Cause of Death register. The diagnose heart failure refer to patients diagnosed 
during hospitalization. Time to follow-up was from July 2006 to December 2012 at 
the most. 
Study IV
This cohort study included hypertensive patients with dispense of 3 or more antihy-
pertensive drugs from the Swedish primary care cardiovascular database (SPCCD) 
from 2006 to 2008. All patients with a blood pressure measurement after 1 July 2006 
were eligible for inclusion, but only patients with a PDC ≥80% on 3 or more antihy-
pertensive drug classes were included. Two comparable patient groups were formed 
according to their baseline blood pressure level, ≥140/90 mm Hg (TRH) and <140/90 
(controlled). We excluded patients with a history of ischemic heart disease, heart fail-
ure, stroke or TIA. Also, patients with a PDC <80%, with multi dose dispensing or 
with diagnosed secondary hypertension were excluded.
We measured drug adherence longitudinally through PDC level during 365 and 730 
days after the index blood pressure which was the last measured blood pressure in 
the database. Adherence to treatment with 3 or more antihypertensive drug classes, at 
these time points, was the defi ned outcome in the study. To be classifi ed as adherent 
a continuous PDC ≥80% for 3 antihypertensive drugs during the defi ned time periods 
was required. PDC was measured by counting numbers of days supplied by medica-
tions divided by the number of days in the measurement period (i.e 365 or 730 days) 
(Figure 7). 
ш80%PDC PDC
PDCfor
1year
PDCfor
2years
0
Index
Ͳ 180 365 730
Days
Figure 7. Illustration of the study design. Mean PDC of ≥80% for three antihypertensive 
drug classes during 180 days before index blood pressure was mandatory for inclusion. The 
time axis is individual for each patient. All index blood pressures are measured after 1 July 
2006. PDC=Proportion of days covered.
Statistics
Study I
To compare the groups by incident hypertension we used the Chi-2 and the Students 
t-test for categorical and continuous variables respectively. To model the dependence 
on probability for hypertension we used multiple logistic regression analysis. We 
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chose the most predictive models for hypertension by applying the Akaike informa-
tion criteria, Hosmer-Lemeshow test and area under the ROC-curve. All models were 
adjusted for age, sex, BMI and smoking. To make the results more comprehensible we 
created a risk chart describing the absolute risk of developing hypertension 10 years 
after an exercise test. The risk chart was based on the model with the best predictive 
value which included systolic blood pressure before exercise and increase in SBP over 
time and workload. Statistical analysis was made using SAS 9.2.
Study II
We presented the baseline data as means +/- SD or percentages as appropriate. For 
between group comparisons we used the Chi-2 and the Students t-test for categorical 
and continuous variables respectively. To describe the prevalence in each category we 
used the treated hypertensive study population as a denominator.
To model the dependence of having TRH from different patient characteristics and 
co-morbidities we used a Poisson regression analysis (89). We made adjustments for 
age, sex, smoking and co-morbidity. Data are presented as prevalence ratios with 95% 
confi dence intervals (CI). Statistical analysis was made using SAS 9.3.
Study III
Baseline data was presented as means +/- SD or percentages as appropriate. To com-
pare the groups we used Poisson regression analysis (89) for unadjusted model and 
Cox-regression analysis to adjust for the possible confounders age, sex, smoking, 
BMI, level of education, country of birth, level of income, diabetes (type I and II) and 
atrial fi brillation. We performed the analysis in a stepwise manner and adjusted for 
possible confounding factors in three different models.
To strengthen the validity of the study we used multiple imputation for missing data 
on smoking and body mass index. Multiple imputation is a way of dealing with miss-
ing data. Imputed data is created by using observed data in multiple regression models 
and the advantage over single imputation is that it accounts for the uncertainty as-
sociated with the missing values (90). We compared results from the Cox-regression 
analysis from complete/observed data with results from data derived from multiple 
imputation. Statistical analysis was made using SAS 9.3.
Study IV
We presented the baseline data as means +/- SD or proportions as appropriate. Dif-
ferences in baseline data were evaluated using the Students t-test and the Chi-2 for 
continuous and categorical variables. To test between group differences in PDC-level 
we applied the Mann-Whitney-U-test. To describe factors associated with non-adher-
ence in this population, treated with 3 or more antihypertensive drug classes we used 
a Poisson regression analysis (89). Non-adherence was the outcome measure in the 
regression analysis and was defi ned as PDC <80% at 1 or 2 years. Co-variates with 
infl uence on adherence level were treatment resistant hypertension, age, sex, diabetes 
mellitus, renal function, and educational level, country of birth, annual income, and 
index blood pressure level. Statistical analysis was made using SAS 9.3.
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RESULTS
Study I
The response rate to the questionnaire was 58% (352/606). Because of incomplete 
information in the questionnaire or resting blood pressure before exercise of ≥180 mm 
Hg before the exercise test we excluded 58 patients. Among the remaining 294 pa-
tients, 9 subjects were diagnosed with cardiovascular disease (myocardial infarction, 
angina pectoris or stroke) at the time of the exercise test. Of the evaluated patients 244 
were outpatients and 35 were hospital-admitted. Fifteen patients had unknown refer-
ral status. Individuals who were hypertensive at follow-up had a higher BMI and were 
more often found to be smokers at the time of the exercise test.
Out of 294 subjects, 67 (23%) reported hypertension at the 10-12 year follow-up in 
2007-2008. 
Patients who were hypertensive at follow-up had on average a higher SBP before the 
exercise test and had a steeper rise in SBP during the test compared to patients who 
stayed normotensive (Figure 8).
Figure 8. Systolic blood pressure during exercise (mean value ± 1 s.e.) by incident hypertension 
as a function of time, separately for women and men. The horizontal line indicates 190 mm Hg for 
women and 210 mm Hg for men, respectively.
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From the multiple logistic regression analysis we found that the best model to predict 
hypertension at follow-up was SBP before exercise in combination with blood pres-
sure increase over time (OR 1.63; 95% CI 1.31-2.01). To describe the absolute risk of 
developing hypertension from the best predictive model we created a risk chart based 
on systolic blood pressure before exercise (SBP0), rate of increase in SBP over time 
(rate [mm Hg/min]) and BMI (Figure 9).

Figure 9. Predicted probability for 10-year incidence of hypertension (%). Chart based 
on systolic blood pressure before exercise, rate of blood pressure increase over time 
and body mass index (BMI).
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Study II
We identifi ed 53 125 individuals diagnosed with hypertension who had at least one 
dispensed antihypertensive drug during the study period. Compared to the non-TRH 
group, patients with TRH were older, had a higher systolic blood pressure and more 
co-morbidity. 
According to the fi ve different defi nitions applied the prevalence of TRH was 8-17%. 
The highest prevalence was found when combining controlled and uncontrolled TRH. 
The lowest prevalence was found in the defi nition including mineralocorticoid recep-
tor antagonist treatment. Women had higher prevalence of uncontrolled TRH. But, 
when combining controlled and uncontrolled TRH, there was no gender difference. 
The prevalence of TRH increased with age, but a substantial proportion of TRH was 
observed in the youngest age group, 30-49 years (Table 2). 
Table 2. The prevalence of treatment resistant hypertension (TRH) in women and men 
by the different defi nitions.
DefinitionsofTRH Women Men Differencein
prevalence
Womenand
Men
(n=29917) (n=23173)
 SBP±SD DBP±SD SBP±SD DBP±SD P 
(%) (mmHg) (%) (mmHg)
1a)SBPш140and/orDBPш90
mmHgwith3ormoredrugs
dispensed,ofwhichoneisa
thiazidediuretic
9.4 153±15 79±10 8.4 151±13 82±10 <0.001 
1b)SBPш140and/orDBPш90
mmHgwith3ormoredrugs
dispensed,regardlessofdrug
class
14.5 153±14 79±10 13.4 151±13 82±10 0.002 
2)SBP<140and/orDBP<90
mmHgwith4ormoredrugs
dispensed,regardlessofdrug
class
2.9 125±10 71±9 3.8 125±10 72±9 <0.001* 
3)TRHaccordingtoanyofthe
definitions1a,1bor2 17.4 148±17 78±11 17.2 145±17 80±11 0.5 
4)SBPш140and/orDBPш90
mmHgwith3ormoredrugs
dispensed,ofwhichoneisan
MRA
1.2 151±15 77±11 0.9 152±15 80±11 0.002 
5)SBPш160mmHgwith3or
moredrugsdispensed,
regardlessofdrugclass
4.5 170±12 82±11 3.7 169±11 85±11 <0.001 
SD=standard deviation; TRH=treatment-resistant hypertension; MRA=Mineralocorticoid receptor antago-
nist. SBP/DBP represent means +/- SD. *Signifi cantly more men. 
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We found that diabetes mellitus (type I and II) (prevalence ratio [PR] 1.59; 95% CI 
1.53-1.66), ischemic heart disease (PR 1.25; 95% CI 1.20-1.30), heart failure (PR 
1.55; 95% CI 1.48-1.64), atrial fi brillation (PR 1.33; 95% CI 1.27-1.40) and chronic 
kidney disease (PR 1.38; 95% CI 1.23-1.54) were all associated with having TRH. 
Stroke/TIA (PR 1.04; 95% CI 0.98-1.09) or being a smoker (PR 0.97; 95% CI 0.89-
1.05) was however not associated with having TRH (Figure 10).

Figure 10. Prevalence ratios for treatment resistant hypertension (TRH) associated with 
patient characteristics and cardiovascular diagnosis.
Study III
We found 4 317 patients with TRH and 32 282 with non-TRH among the 36 599 
patients with treated hypertension and without a history of previous cardiovascular 
disease, corresponding to a TRH prevalence of 12%. 
Regarding baseline characteristics, patients with TRH, compared to non-TRH, were 
older, less often smokers, had higher SBP, lower estimated glomerular fi ltration rate 
(eGFR), and were more often diagnosed with diabetes mellitus and atrial fi brillation. 
The mean follow-up time was 4.3 years regarding total mortality, cardiovascular mor-
tality, ischemic heart disease, heart failure, stroke and TIA. During follow-up a total 
of 3 851 patients died, 31% of deaths were caused by cardiovascular disease. In the 
whole study population of 36 599, 2 048 patients were diagnosed with ischemic heart 
disease and 1 476 with heart failure, 1 666 with stroke and 473 with TIA. When com-
paring the TRH and the non-TRH patients with respect to the specifi c cardiovascular 
outcomes through a regression analysis we found in the unadjusted model that pa-
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tients with TRH had a signifi cantly higher incidence rate ratio (IRR) for all outcomes 
compared to patients with non-TRH. However, in the fully adjusted model patients 
with TRH had a remaining increased risk of total mortality (HR 1.12; 95% CI, 1.03-
1.23), cardiovascular mortality (HR 1.20; 95% CI, 1.03-1.40), and heart failure (HR 
1.34; 95% CI, 1.17-1.54). The risk for ischemic heart disease, stroke and TIA was not 
signifi cantly increased (Figure 11). The results from the different models derived from 
the Cox-regression analysis illustrate the impact of blood pressure level, of socioeco-
nomic situation and of metabolic disturbances on the specifi c outcomes. The results 
were consistent when data from complete cases before imputation (smoking, BMI, 
LDL and eGFR) were compared to the results with the imputed data set. 
Study IV
In the population eligible for inclusion we found 3 508 patients with TRH (blood pres-
sure ≥140/90 mm Hg) and 2 338 patients with controlled hypertension (blood pres-
sure <140/90 mm Hg) despite adherence to 3 or more antihypertensive drug classes. 
The mean systolic blood pressure in the TRH group was 152 mm Hg and 128 mm 
Hg in the controlled group. Patients with TRH were found to be older (69.1 vs. 65.8 
years, p<0.0001) and to have higher LDL-levels (3.2 vs. 3.1 mmol/L, p<0.0001). In 
the TRH group there were a smaller proportion of patients with diabetes compared to 
controlled patients (28.5 vs. 31.7%, p=0.009). Further, in the TRH group there were 
more women (61 vs. 57%, p=0.003) and a lower mean annual income level. Number 
of drugs exceeding the 3 that was mandatory to be included in the study were similarly 
distributed between the groups.
Figure 11. Results from the Cox regression analysis comparing patients with treatment 
resistant hypertension and patients with non-treatment resistant hypertension. Adjust-
ment for age, sex, smoking, diabetes mellitus, atrial fi brillation, BMI, systolic blood pres-
sure, eGFR, LDL, cancer, country of birth, education and income level.
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At the time of the index blood pressure every patient included had a PDC level ≥80%. 
During the fi rst year of the study the decline in proportion of patients keeping the PDC 
level ≥80 % declined to 89% in both groups with a further decline in the controlled 
group to 87% compared to the TRH group who stayed at 89% even at 2 years.
From the Poisson regression analysis we found that having TRH was not associated 
with a PDC <80% at 1 (RR 0.99; 95% CI 0.79-1.23) or 2 years (RR 0.87; 95% CI 
0.71-1.08). Being diagnosed with diabetes was associated with staying at a high PDC 
level (RR 0.82; 95% CI 0.68-0.98). However, being born outside Europe was associ-
ated with having a lower adherence level after 1 (RR 2.05; 95% CI 1.49-2.82) and 2 
years (RR 2.27; 95% CI 1.70-3.03) (Figure 12).  

Figure 12. Forest plot describing the associations from different factors 
on having PDC <80% at 1 year. Positive association (>1.0). Negative 
association (<1.0). *Reference categories for the regression analysis. 
**RR for every 10 mm Hg index blood pressure increase for having 
PDC <80%.
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 DISCUSSION
Is it possible to predict onset of hypertension using data from exercise 
testing? 
The exercise test is primarily designed to reveal arrhythmias and cardiac ischemia. 
The idea of using the test for additional scientifi c questions stems from the fact that 
during every single test much hemodynamic data can be collected. Other underlying 
causes are the wish to have prognostic tools for cardiovascular disease at an early 
stage and to predict disease development for the future. The importance of identify-
ing individuals with increased risk of future hypertension could on the other hand 
be questioned since there are scarce evidence that treatment should be initiated in 
pre-hypertension (91), and it is important to focus on proper blood pressure measure-
ment (offi ce blood pressure, ambulatory blood pressure monitoring and home blood 
pressure) proven to be linked to cardiovascular outcome. There have been several 
scientifi c attempts to use the exercise test as a predictive tool for a variety of diagnoses 
and outcomes. It has been suggested that the risk for future atrial fi brillation can be 
predicted from a high blood pressure during exercise testing (92). From a Norwegian 
cohort of normotensive, healthy, middle-aged men several publications have claimed 
the usefulness of a high blood pressure during exercise as a predictor for death due to 
myocardial infarction (45) and cardiovascular death (44). Further, the risk of stroke 
(93; 94) and the unmasking of heart failure with preserved ejection fraction (95) has 
been suggested to be predicted from the blood pressure reaction recorded during stan-
dardized exercise. 
In study I we conclude that the best predictor for future hypertension in both men and 
women is high baseline blood pressure and a steep rise in blood pressure over time. 
Previous investigations have found a mechanistic explanation linking high blood 
pressure during exercise test to augmented aortic stiffness, altered endothelial func-
tion (96) and increase in carotid intima media thickness (97). 
The ESH concluded in their guidelines from 2013 that exercise testing is not rec-
ommended for prediction of future hypertension mainly because of the diversity in 
methodology in present studies and the fact that there is no consensus regarding which 
blood pressure measurement that has the best predictive value (5). However, the same 
guidelines state that there might be an indication for ABPM in patients with hyperten-
sive response to exercise because this blood pressure measurement can reveal masked 
hypertension (98).
Since the publication of our study I and the ESH guidelines in 2013 several studies 
with the intention to investigate the predictive value of exaggerated blood pressure 
response to exercise testing have been performed. It is suggested that a peak SBP 
of 181 mm Hg may be a predictor of future hypertension (99). Also a meta-analysis 
published in JACC conclude that high blood pressure during exercise, despite various 
defi nitions, can predict incident hypertension (100). However, there are also recent 
studies where no relation between high blood pressure at exercise and future hyper-
tension has been identifi ed (101).
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An interesting fi nding is that high SBP during exercise in the elderly might rather 
predict a good prognosis since the possibility to produce a high blood pressure during 
exercise in the elderly may be a sign of preserved cardiac output (102). 
In conclusion, many studies have shown that exaggerated blood pressure in response 
to exercise testing, independent of methodology, is a predictor for future hyperten-
sion. Still there are some different defi nitions of hypertensive response to exercise 
testing and many physicians are still not confi dent in interpreting the blood pressure 
response during the test. 
One help for interpretation of the blood pressure reaction could be a simple risk chart. 
We have published a suggestion of how such a risk chart could be created. However, 
this predictive risk chart ought to be evaluated in larger populations with more strict 
measurements of the outcome variables before it could be introduced in clinical prac-
tice. 
The exercise test holds information about the cardiovascular status of apparently 
healthy individuals or at least the individuals referred for exercise testing that of 
course is a selected population. If we can identify individuals with masked hyperten-
sion by the exercise test we might be able to diagnose more individuals with hyper-
tension or initiate follow-up of individuals in this particular population. This could be 
one contribution to increase awareness regarding hypertension among physicians and 
patients.
What is the prevalence of treatment resistant hypertension?
Treatment resistant hypertension has various defi nitions in different guidelines (5; 
59). In Europe a commonly used defi nition of TRH is blood pressure ≥140/90 mm Hg 
despite the use of 3 or more antihypertensive drug classes, of which one is a thiazide 
diuretic (5). In study II our aim was to present a summary of all prevailing defi nitions. 
We found the prevalence of TRH to be between 8 and 17% depending on the defi ni-
tion used. 
Previous attempts to describe the prevalence of TRH from hypertension RCT´s (103; 
104), population based studies (105; 106) and retrospective analysis of registry data 
(107; 108) all report a prevalence between 8-15% which make our study partly con-
fi rmatory but extend the knowledge to a larger population in Sweden with valid phar-
macy refi ll data.
Women have been found to have more uncontrolled TRH, i.e. blood pressure ≥140/90 
mm Hg despite the use of 3 or more antihypertensive drug classes, both in our study 
II and in previous investigations (105; 106; 109). This is also in line with previous 
fi ndings in the SPCCD cohort where women have been found to have higher attained 
blood pressure levels (110). In the study by Ljungman et. al. one explaining factor 
was thought to be the choice of antihypertensive drug classes, since women more of-
ten were prescribed beta-blockers and diuretics while men primarily were prescribed 
calcium channel blockers and ACE-inhibitors. We do not know if this prescription 
difference, with respect to gender, holds true for our patients with TRH but it is pos-
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sible to consider that different prescriptions to men and women might contribute to 
our fi ndings regarding gender differences since patients with TRH are selected from 
the same SPCCD cohort as the cohort mentioned above.
We found that when including a mineralocorticoid receptor antagonist into the defi ni-
tion of TRH a prevalence of 1.1% was found. Only 8% of patients with TRH and 4% 
in the group without TRH were prescribed a mineralocorticoid receptor antagonist. 
Explaining factors for not using mineralocorticoid receptor antagonists to a higher 
extent are not easily found in the present study but possible factors could be renal 
impairment or the fact that treatment with mineralocorticoid receptor antagonists is 
affl icted with several side effects. Further, mineralocorticoid receptor antagonist is a 
second line treatment and might be considered as an old fashioned treatment strategy 
since the introduction of better tolerated antihypertensive drugs during the 80´s and 
90´s century. Mineralocorticoid receptor antagonists are considered less studied in 
terms of cardiovascular risk reduction compared to other treatment options. 
Previous studies have however revealed that mineralocorticoid receptor antagonists 
are effi cient regarding blood pressure lowering effect (111; 112). To test the hypoth-
esis whether sodium retention is the most common cause of resistant hypertension 
Williams and co-workers designed the PATHWAY-study. In this RCT a fourth drug 
was added on top of standard treatment with ACE-inhibitor, calcium channel blocker 
and thiazide-like diuretic in patients with TRH. The mineralocorticoid receptor antag-
onist, Spironolactone, was found to have the best blood pressure lowering effect. This 
implies that TRH might be a result of fl uid retention and can be diminished by diuretic 
therapy, especially mineralocorticoid receptor antagonist, at suffi cient doses (113). 
Further, since the proportion of undiagnosed primary aldosteronism in the hyperten-
sive population, and especially in the subpopulation with TRH, Spironolactone seems 
to be a proper drug of choice. In the PATHWAY-study the renin levels at baseline in 
patients with TRH were low indicating that there might be an undiagnosed distur-
bance in the aldosterone-renin system explaining some of the TRH cases. Our study 
shows that there is room for an increase in prescription of mineralocorticoid receptor 
antagonists and together with the evident effi cacy as a blood pressure lowering agent 
this should encourage physicians to reappraise the use of mineralocorticoid receptor 
antagonists in hypertensive patients. 
The diagnosis with the strongest association to TRH was diabetes mellitus. It is well 
known that diabetes co-exist and share common pathophysiology such as altered mi-
crocirculation with hypertension (114). High-normal blood pressure has been sug-
gested as a predictor for onset of type 2 diabetes in extended follow-up over thirty-
fi ve years time (115). Furthermore, patients with diabetes have higher attained blood 
pressure levels (116) and it has been found that it is more diffi cult to control blood 
pressure in patients with diabetes (117). At the same time patients with diabetes are 
signed up for regular visits at the PHCC´s for control of their diabetes and blood pres-
sure, which ought to result in better control. This should be an opportunity to tailor the 
antihypertensive treatment to reach target blood pressure levels.
The challenge of describing the prevalence of TRH is partly due to the fact that one 
must try to distinguish apparent TRH (aTRH) from true TRH. From population based 
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and registry based studies it is only possible to describe the prevalence of aTRH. 
However, there is potential to get closer to the prevalence of true TRH. Our approach 
was to only include patients with high medication adherence and exclude patients with 
known and diagnosed secondary causes to hypertension. To describe the prevalence 
of true TRH one would need to initiate a cohort especially designed for describing true 
TRH. This would be costly and require a lot of effort. By describing the prevalence of 
TRH you can acquire an estimate of how many patients that could be considered for 
a more systematic screening for secondary causes of hypertension. Further, this work 
can direct attention towards TRH and associated factors. Hopefully by focusing on 
this patient group the well known methods of controlling blood pressure such as strict 
medication adherence, life-style factor intervention and treating secondary causes can 
once again be appraised.
What is the outcome in treatment resistant hypertension?
Patients with TRH, in study III, were found to have an increased risk for heart failure 
during the time of follow-up. Hypertension is a well-known risk factor for heart fail-
ure (118). In the Swedish Heart Failure registry as many as 61% of the patients with 
heart failure with preserved ejection fraction have concomitant hypertension (65). 
Heart failure is a disease with poor prognosis (119) and the prognosis is comparable 
to several common cancer forms (120). 
It has been described that controlling blood pressure is a proper way to decrease the 
incidence of heart failure (121). Since TRH patients per se do not reach target blood 
pressure levels it is not surprising that they carry an over-risk for heart failure. This 
has also been demonstrated in previous studies with partly different design compared 
to our study III. In a post-hoc analysis from patients not reaching target blood pressure 
in the RCT “ALLHAT” performed in the late 90´s century heart failure was signifi -
cantly higher in TRH patients (67). In RCT´s the medication adherence is thought to 
be good but the choice of medications is limited to the study protocol which can make 
it more diffi cult to interpret in the clinical setting. 
In our study III we did not, after multivariate adjustments, fi nd an association between 
TRH and stroke/TIA. This was at fi rst surprising since hypertension is a well-known 
risk factor for stroke (122) and lower blood pressure levels are protective especially 
for stroke (53). The results are however in line with a previous study assessing the 
cardiovascular risk for TRH (123). Possible explaining factors in our investigation 
can be low mean age in both groups and the fact that we are comparing two groups 
with hypertensive patients who both have increased risk for stroke. It has further been 
suggested that stroke is an entity that primarily has hypertension as a risk factor (123) 
while ischemic heart disease and heart failure share common risk factors with TRH 
beyond high blood pressure such as primary aldosteronism and sleep apnea. All these 
factors could partly explain the lack of differences in stroke outcome found in study 
III (124-126).
Diabetes was more common in the TRH group. As a result we adjusted for this vari-
able in the multivariate analysis. It is not obvious if diabetes is a mediator or a con-
founder for the correlation between TRH and, for example, stroke. In the unadjusted 
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analysis the association between TRH and stroke was strong and when adjusting for 
diabetes, among other things, the association was no longer signifi cant which might 
indicate that diabetes is one of the mediators of the effect from TRH on stroke (127).
Medication adherence
According to guidelines medication adherence should always be considered in pa-
tients who do not reach blood pressure target levels (5). 
We evaluated the medication adherence during two years in patients dispensed 3 or 
more antihypertensive drug classes with high medication adherence at baseline with 
both uncontrolled blood pressure (≥140/90 mm Hg) and controlled blood pressure 
(<140/90 mm Hg). 
We found an equal decline in medication adherence to 3 or more antihypertensive 
drug classes in both patients with controlled blood pressure and patients with uncon-
trolled blood pressure at baseline. Since it has been described that low medication 
adherence is common in TRH (128) we hypothesized that this might be refl ected in a 
difference in medication adherence between uncontrolled and controlled hypertensive 
patients even in this selected population with patients verifi ed to be highly adherent 
at baseline. Lower adherence for TRH patients has been previously described (129). 
On the other hand, the same phenomenon as in our study has been observed in earlier 
studies from North America (68). Since we do not have data on blood pressure de-
velopment during these two years it is diffi cult to make any further conclusions from 
these fi ndings. 
In paper IV we further found that having diabetes was associated with having PDC 
≥80% during both years studied. It has previously been described that blood pressure 
level generally is higher in patients with diabetes (130) and it has also been described 
that diabetes is associated with additional diffi culty to control hypertension (117). 
Patients with diabetes ought to have a good chance of being evaluated for medication 
adherence since they have regular visits at the PHCC´s. Further, it might be likely that 
patients diagnosed with a disease that produce negative symptoms in relation to insuf-
fi cient medication adherence will be more compliant to other medications as well. 
In the clinical setting there are several ways of evaluating medication adherence. In 
a Norwegian study direct observation of drug intake in the clinic was seen to reduce 
TRH immensely (131). This is the only way to be positive regarding if the patients 
are actually taking their medication, but it is of course impossible to practice this regi-
men in real life. Another method described is “Therapeutic drug monitoring” which 
implies screening for drug concentrations in blood and urine. This method has been 
shown cost-effective in patients with TRH (132). Registry studies are not suitable 
for these kinds of medication adherence assessments, but enable us to use a different 
method in evaluating drug adherence. To estimate prescribed medication is one way 
but, to investigate dispensed drugs is even more accurate and gives a better oppor-
tunity to answer the question whether the patients are taking their medication or not 
(133). In Sweden we have a unique pharmacy claims registry with full coverage of all 
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dispensed drugs to all citizens (87) which makes evaluation of medication adherence 
with this method accurate.
Low medication adherence in hypertension is common and maybe, by describing 
medication adherence in a population with multiple antihypertensive drug use we can 
gain more insight in this challenging subject and hopefully overcome some of the bar-
riers to treatment that exists.
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CONCLUSIONS AND FUTURE PERSPECTIVES
It is possible to predict development of hypertension from an exercise test. In fact 
many patients with undiscovered hypertension have high blood pressure already be-
fore the exercise test starts. Using the information from exercise testing can help fi nd, 
follow and treat more hypertensive patients and could contribute to diminishing the 
global burden of the disease from hypertension.
The prevalence of treatment resistant hypertension varies between 8 and 17% accord-
ing to which defi nition you chose to apply. Treatment with mineralocorticoid receptor 
antagonists does reduce the prevalence, but treatment resistant hypertension is still 
not a negligible problem in the hypertensive population. Increasing the use of miner-
alocorticoid receptor antagonists will probably decrease the prevalence of treatment 
resistant hypertension and the blood pressure levels in this hypertensive population.
Patients with treatment resistant hypertension seem to have an increased risk for heart 
failure, cardiovascular mortality, total mortality and ischemic heart disease compared 
to other patients with hypertension not resistant to treatment. Although hypertension 
is known to be the strongest risk factor for stroke we did not fi nd a strong associa-
tion between treatment resistant hypertension and stroke/TIA. Putting extra effort into 
controlling blood pressure and search for causes of secondary hypertension, especial-
ly primary aldosteronism, is recommended if we want to reduce the enhanced risk for 
unbenefi cial cardiovascular outcomes for patients with apparent treatment resistant 
hypertension. Especially the increased risk for heart failure is important since heart 
failure has an increasing prevalence in Sweden (134) and is a disease with progno-
sis comparable to many cancer forms. This knowledge once again should encourage 
care-givers to take action to control blood pressure and try to diminish the burden of 
disease from hypertension.
In a patient cohort of hypertensive patients with high medication adherence to mul-
tiple antihypertensive drugs there is a similar decline in mean medication adherence 
over two years time between patients with treatment resistant hypertension and pa-
tients with controlled hypertension. Patients with diabetes are more prone to have a 
high medication adherence emphasizing that structured care-giving is benefi cial for 
high medication adherence. The results reappraise that hypertensive patients ought 
to have the possibility to have structured care-giving and hopefully reminds us of 
the known ways to enhance blood pressure control through home blood pressure and 
fi xed dose combinations. 
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LIMITATIONS
All the studies in this thesis are observational to their character and hence they all 
have the inherent limitations of this kind of studies such as selection bias, unknown 
confounding factors, missing values and misclassifi cation.
Study I
All exercise tests during a certain time-period were eligible for inclusion but almost 
half of them were excluded from further analysis. We do not think that these missing 
data are dependent on the outcome variable, hypertension. The missing values from 
unanswered questionnaires could be dependent on the diagnosis of hypertension but 
it is impossible to know what infl uence this had on the effect-size. The outcome vari-
able, hypertension, is measured through a questionnaire that was not validated, which 
can lead to misclassifi cation regarding the outcome variable. 
The fact that the study included patients who performed the exercise test on different 
indications make the study generalizable to the clinic situation in the ward of Clini-
cal physiology were most exercise tests are performed but can also be misinterpreted 
since some individuals are healthy fi remen and others are patients hospitalized for 
chest pain.
Study II-III
Patients who are unaware of their hypertension are not included in the SPCCD since 
they were not diagnosed in the PHCC. This bias could only be diminished by initiat-
ing a cohort study randomising individuals from the population for the purpose of 
screening for hypertension and TRH.
Since we have the treated hypertensive population as a denominator in the prevalence 
calculation the prevalence numbers should be valid regarding the prevalence of TRH 
in the treated hypertensive population. 
We used one single blood pressure to classify patients with TRH which might pro-
duce some bias with respect to misclassifi cation. However, analyses of blood pressure 
measurements in the SPCCD reveal that the last recorded blood pressure is represen-
tative of the last three measurements. Both diagnosis of hypertension, co-morbidities 
and outcome variables rely on registration of ICD-codes in medical records or diag-
nose registers. However, a validation of the diagnosis registration in one region of 
the SPCCD shows that the mean sensitivity for hypertension ICD-code is 83% (135). 
In study III we used multiple imputation to try to diminish the infl uence from missing 
values in the SPCCD on the results. In multiple imputation you need to assume that 
the missing data are missing randomly i.e. not depending on the explaining variable 
or the outcome variable. We made this assumption for the analysis of BMI, smoking, 
LDL and eGFR which all had a large proportion of missing values.
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In the SPCCD we miss information on several factors infl uencing blood pressure such 
as level of physical activity, alcohol consumption, perceived stress, salt-intake and 
sleeping disorders. The missing information on these parameters is equal for all pa-
tients and thus does not directly infl uence the results for between group comparisons. 
Also, when describing apparent TRH, like we did, it is not mandatory to exclude sec-
ondary causes of hypertension. 
Study IV
In study IV we investigate individuals with known high adherence which limits the 
results to only describe a decline in medication adherence. Another limitation in this 
study is the fact that we compare the mean values of the two groups which possibly 
mask a true medication adherence increase in some cases and decrease in some cases. 
We do not follow blood pressure longitudinally and it is unknown to us whether the 
patients have a controlled blood pressure or not after one and two years or not. Blood 
pressure control might of course have had infl uence on medication use during this 
time period.
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